Saudi Arabia announces a plan to become a biotech leader in the Middle East and North Africa region by 2030 and an international biotech hub by 2040. Its National Biotechnology Strategy aims to grow the country’s capabilities in vaccines, biomanufacturing, genomics and plant optimization to increase job creation and drive economic growth and diversification.

The Ministry of Health and Welfare invests $187 million in the biotech sector through its K-Bio/Vaccine No. 1 and No. 2 Funds. The government will combine two private fund management companies, which will begin making full-scale investments over the next four years. Phase 2–3 trials of innovative medications, platforms and vaccine technologies are the investment targets.

沙特阿拉伯宣布计划到 2030 年成为中东和北非地区生物技术领导者，到 2040 年成为国际生物技术中心。其国家生物技术战略旨在提高该国在疫苗、生物制造、基因组学和工厂优化方面的能力，以增加就业机会创造并推动经济增长和多元化。

卫生和福利部通过其 K-Bio/疫苗 1 号和 2 号基金向生物技术领域投资 1.87 亿美元。政府将合并两家私募基金管理公司，并在未来四年内开始进行全面投资。创新药物、平台和疫苗技术的2-3期试验是投资目标。